Structure Therapeutics (GPCR) said Monday patients who took a high dose of its GLP-1-targeted obesity treatment lost up to 15.3% more body weight than placebo recipients. Structure Therapeutics stock rose sharply in early trades.
The results support plans to begin a Phase 3 study in mid-2026, Structure said in a news release. Chief Executive Raymond Stevens said patients who took the higher doses lost weight over the course of 36 weeks without hitting a plateau. This could represent best-in-class results for a GLP-1 drug, he said in a statement.
"More importantly, these findings provide comprehensive information to move into Phase 3 development and reinforce aleniglipron's potential to become a backbone oral small molecule therapy for obesity — one that is accessible, scalable, and combinable," he said.
Structure stock catapulted more than 30% to 45.50. Shares are already trading above their 50-day and 200-day moving averages. If the move holds, the stock will open at its highest point in 14 months
https://www.investors.com/news/technology/structure-therapeutics-stock-weight-loss-drug/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.